News May 1, 2024 NFlection Therapeutics Announces Publication of Clinical Data Demonstrating the Effect of NFX-179 Topical MEK Inhibitor on Cutaneous Neurofibromas in Persons with Neurofibromatosis Type 1Read More November 13, 2023 NFlection Therapeutics Announces Positive Results from Phase 2b Study of NFX‑179 Topical Gel in the Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1Read More October 11, 2023 Novel Drug, NFX-179, Inhibits MEK Activity, Prevents Cutaneous Squamous Cell Carcinoma DevelopmentRead More December 23, 2022 Children’s Tumor Foundation Expands into a New Strategic Chapter as Impact Investor in NF ResearchRead More October 18, 2021 NFlection Therapeutics Appoints William Hodder as CEO and Expands Leadership Team to Accelerate Development of Targeted Treatments for Rare DiseasesRead More August 18, 2021 NFlection Therapeutics Announces Orphan Drug Designation of NFX-179 for the Treatment of Cutaneous Neurofibromatosis Type 1 | Business WireRead More May 26, 2021 NFlection Therapeutics’ NFX-179 Gel Demonstrates Safety and Significant Reduction in p-ERK, a Key Biomarker Driving Neurofibroma Tumor Growth, in Positive Data From a 28-Day Phase 2a Clinical TrialRead More May 4, 2021 Topical MEK Inhibitor, NFX-179, Prevents Cutaneous Squamous Cell Carcinoma in Pre-Clinical Model.Read More June 9, 2020 NFlection Therapeutics Launches with $20M Series A Funding to Advance Lead Program in NeurofibromatosisNFlection Therapeutics Launches with $20M Series A Funding toRead More